UA84046C2 - Лечение остеопороза, ассоциированного с терапией ингибиторами ароматазы - Google Patents

Лечение остеопороза, ассоциированного с терапией ингибиторами ароматазы

Info

Publication number
UA84046C2
UA84046C2 UAA200607823A UAA200607823A UA84046C2 UA 84046 C2 UA84046 C2 UA 84046C2 UA A200607823 A UAA200607823 A UA A200607823A UA A200607823 A UAA200607823 A UA A200607823A UA 84046 C2 UA84046 C2 UA 84046C2
Authority
UA
Ukraine
Prior art keywords
treatment
aromatase inhibitor
inhibitor therapy
related osteoporosis
osteoporosis
Prior art date
Application number
UAA200607823A
Other languages
English (en)
Ukrainian (uk)
Inventor
Саймон Н. Дженкинс
Барри С. Комм
Пол Буде
Филип Фрост
Метью Л. Шерман
Original Assignee
Уайет
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Уайет filed Critical Уайет
Publication of UA84046C2 publication Critical patent/UA84046C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
UAA200607823A 2004-01-13 2005-01-11 Лечение остеопороза, ассоциированного с терапией ингибиторами ароматазы UA84046C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53603504P 2004-01-13 2004-01-13
PCT/US2005/000803 WO2005070434A2 (en) 2004-01-13 2005-01-11 Treatment of aromatase inhibitor therapy-related osteoporosis

Publications (1)

Publication Number Publication Date
UA84046C2 true UA84046C2 (ru) 2008-09-10

Family

ID=34806981

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200607823A UA84046C2 (ru) 2004-01-13 2005-01-11 Лечение остеопороза, ассоциированного с терапией ингибиторами ароматазы

Country Status (19)

Country Link
US (1) US20050272717A1 (ru)
EP (1) EP1703910A2 (ru)
JP (1) JP2007517899A (ru)
KR (1) KR20060127875A (ru)
CN (1) CN1929835A (ru)
AR (1) AR048394A1 (ru)
AU (1) AU2005206137A1 (ru)
BR (1) BRPI0506774A (ru)
CA (1) CA2552725A1 (ru)
CR (1) CR8495A (ru)
EC (1) ECSP066699A (ru)
IL (1) IL176628A0 (ru)
NO (1) NO20063448L (ru)
PA (1) PA8621401A1 (ru)
RU (1) RU2006123939A (ru)
SG (1) SG149081A1 (ru)
TW (1) TW200526206A (ru)
UA (1) UA84046C2 (ru)
WO (1) WO2005070434A2 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1937251A2 (en) * 2005-04-25 2008-07-02 Pfizer Products Inc. Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
AU2012275036B2 (en) * 2005-08-24 2016-05-19 Wyeth Llc Bazedoxifene acetate formulations and manufacturing process thereof
BRPI0615341A2 (pt) * 2005-08-24 2011-05-17 Wyeth Corp composições farmacêuticas contendo acetato de bazedoxifeno, processo para preparação destas e comprimido ou cápsula contendo a referida composição
EP1945224B1 (en) 2005-10-19 2012-05-02 Chavah Pty Ltd Reduction of side effects from aromatase inhibitors used for treating breast cancer
WO2013182169A1 (en) * 2012-06-07 2013-12-12 Zentiva, K. S. Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate
CN103860496A (zh) * 2014-03-14 2014-06-18 王志刚 一种醋酸巴多昔芬分散片及其制备方法
US20160051565A1 (en) * 2014-08-20 2016-02-25 Professional Compounding Centers Of America (Pcca) Transdermal Pharmaceutical Compositions Including Testosterone and an Aromatase Inhibitor
SG11201703279XA (en) 2014-10-22 2017-05-30 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
CN104546794A (zh) * 2015-01-05 2015-04-29 万特制药(海南)有限公司 一种醋酸巴多昔芬胶囊及其制备方法
CN108472302A (zh) 2015-10-22 2018-08-31 哈瓦赫治疗有限公司 降低乳房摄影乳腺密度和/或乳腺癌风险的方法
WO2020243777A1 (en) 2019-06-03 2020-12-10 Havah Therapeutics Pty Ltd Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor and methods for use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW303299B (ru) * 1993-07-22 1997-04-21 Lilly Co Eli
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
US6583170B1 (en) * 1998-05-15 2003-06-24 Wyeth 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
EP1192945A3 (en) * 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
AU2002213198A1 (en) * 2000-10-11 2002-04-22 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
NZ537051A (en) * 2002-06-13 2007-11-30 Wyeth Corp Use of bazedoxifene in an extended dosage treatment regimen

Also Published As

Publication number Publication date
PA8621401A1 (es) 2006-07-03
BRPI0506774A (pt) 2007-05-22
AU2005206137A1 (en) 2005-08-04
NO20063448L (no) 2006-09-29
WO2005070434A2 (en) 2005-08-04
ECSP066699A (es) 2006-10-31
IL176628A0 (en) 2006-10-31
SG149081A1 (en) 2009-01-29
AR048394A1 (es) 2006-04-26
CA2552725A1 (en) 2005-08-04
RU2006123939A (ru) 2008-02-20
TW200526206A (en) 2005-08-16
US20050272717A1 (en) 2005-12-08
WO2005070434A3 (en) 2006-06-08
CR8495A (es) 2007-03-06
KR20060127875A (ko) 2006-12-13
EP1703910A2 (en) 2006-09-27
JP2007517899A (ja) 2007-07-05
CN1929835A (zh) 2007-03-14

Similar Documents

Publication Publication Date Title
SG149081A1 (en) Treatment of aromatase inhibitor therapy-related osteoporosis
ATE516286T1 (de) 5-(ä1,3,4üoxadiazol-2-yl)-1h-indazol und 5-(ä1,3, 4üthiadiazol-2-yl)-1h-indazol derivate als sgk- inhibitoren zur behandlung von diabetes
NO20064124L (no) Anvendelse av metformin og orlistat for behandling eller forebygging av fedme
IL180147A0 (en) N - (1 - (1 - benzyl - 4 - phenyl - 1h-imidazol - 2 - yl) - 2,2 - dymethylpropyl) benzamide derivatives and related compounds as kinesin spidle protein (ksp) inhibitors for the treatment of cancer
MX2007009368A (es) Metodo para estimular la sintesis de colagena y/o expresion de factor de crecimiento de queratinocitos.
NO20075099L (no) Alkynyl-pyrrolopyrmidiner og relaterte analoger som HSP90-inhibitorer
NO20091926L (no) Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer
IL185485A0 (en) Use of pde7 inhibitors for the treatment of neuropathic pain
TW200730168A (en) Combination of an H3 antagonist/inverse agonist and an appetite suppressant
SG166813A1 (en) 5-lipoxygenase-activating protein (flap) inhibitors
IL183709A0 (en) Compositions and methods for treating conditions of the nail unit
WO2009025806A3 (en) Use of vegfr-2 inhibitors for treating metastatic cancer
EP1608361A4 (en) COMPOSITIONS OF SELECTIVE CYCLOOXYGENASE-2 INHIBITORS AND 5-HT1B / 1 D AGONISTS FOR THE TREATMENT AND PREVENTION OF MIGRAINS
MXPA04006572A (es) Terapia de combinacion antivirica.
DE602007011398D1 (de) Trialkylsilylbenzylaminocarboxyindole, indazole und indoline und ihre verwendung zur behandlung von cetp-vermittelten erkrankungen
IL177169A0 (en) Use of n- (2-aryl-propionyl)-sulfonamides for the treatment of spinal cord injury
NO20045343L (no) Ny kombinasjon for behandling av luftveisforstyrrelser
BRPI0514983A (pt) combinação de um agonista do receptor 5-ht(1) e um ligante alfa-2-delta para tratamento da enxaqueca
IL172101A0 (en) Use of indazole derivatives for the treatment of neuropathic pain
HU0001888D0 (en) 5ht1 receptor agonists and either cox-2 inhibitor or nsaid for the treatment of migraine
ECSP055715A (es) Utilizacion de pirimetanilo en patogenos resistentes
ZA200707147B (en) Use of PDE7 inhibitors for the treatment of neuropathic pain
NO20045344L (no) Kombinasjon for behandling av luftveisforstyrrelser
EP1804805A4 (en) USE OF AROMATASE INHIBITORS FOR THE TREATMENT OF ECTOPIC PREGNANCY
WO2008060837A3 (en) Methods and compositions for the treatment of cancer